GleamWall
中文EN

XBIO Xenetic Biosciences, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1534525 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY3.5%
TTM net income YoY-16.0%
TTM EPS YoY24.0%
Revenue 3-yr CAGR7.9%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-129.6%
Net margin-123.7%
FCF margin—
EBITDA margin—

Returns

ROE-87.5%
ROA-64.3%
ROIC (approx.)—
Asset turnover0.52x

Leverage & solvency

Liabilities / assets30.1%
Debt / equity0.00x
Current ratio3.15x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-23.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$2.98M$2.50M
R&D expense$3.07M$3.29M
SG&A expense$2.75M$3.42M
Operating income-$2.83M-$4.20M
Income tax$0$0
Net income-$2.68M-$3.96M
EPS (basic)-1.58-2.57
EPS (diluted)-1.58-2.57
Weighted avg. shares (diluted)1.70M1.54M
Banking
Net interest income$147,997$249,861
Balance sheet
Cash & equivalents$7.88M$6.17M
Current assets$8.05M$6.59M
Total assets$8.36M$6.90M
Current liabilities$968,025$894,263
Total liabilities$968,025$894,263
Shareholders' equity$7.40M$6.01M
Shares outstanding2.29M1.54M
Cash flow statement
Operating cash flow-$2.29M-$2.82M
Financing cash flow$4.00M$0
Stock-based compensation$64,787$171,814

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.